Search

Your search keyword '"McAlpine, Jessica N."' showing total 565 results

Search Constraints

Start Over You searched for: Author "McAlpine, Jessica N." Remove constraint Author: "McAlpine, Jessica N." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
565 results on '"McAlpine, Jessica N."'

Search Results

4. Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test: Performance in a Training and Verification Cohort

6. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers

7. Single-cell genomic variation induced by mutational processes in cancer

8. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification

9. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type

10. Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer

13. VOLTA: an enVironment-aware cOntrastive ceLl represenTation leArning for histopathology

14. Endometrial cancer

15. The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile.

17. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile

19. Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers

20. Abstract B012: Application of shallow whole genome sequencing to identify therapeutic opportunities in p53abn endometrial cancers

21. Abstract PR002: Proteomic profiling of endometrial carcinomas

23. Abstract B031: High risk no specific molecular profile (HR-NSMP) endometrial cancer can be stratified into three subgroups based on tumor grade and estrogen receptor status with differing clinicopathologic characteristics and outcomes

26. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification

27. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

29. AI-based histopathology image analysis reveals a distinct subset of endometrial cancers.

33. Therapeutic options for mucinous ovarian carcinoma

36. FIGO 2023 endometrial cancer staging: too much, too soon?

38. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms

40. DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics

43. Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas

44. Supplementary Figures S1-S4 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas

45. Supplementary Tables S1-S5 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas

46. Data from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas

48. Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling

49. The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas

50. Corrigendum to “Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death”: [Modern Pathology 36 (2023) 100085]

Catalog

Books, media, physical & digital resources